Diagnostics company Accelerate Diagnostics Inc (NASDAQ:AXDX) said on Sunday that it expects total revenues of approximately USD1.8m for the fourth quarter ending 31 December 2018.
This marks a decline when compared with total revenues of USD2.1m in the fourth quarter of 2017.
In the full-year 2018, the company anticipates total revenue to be USD5.7m over total revenue of USD4.2m for full-year 2017.
Net cash, excluding financing, is expected to be about USD14.1m for the Q4 and USD64.1m for full-year 2018.
Commercially contracted instruments in the US rose by 117 in the fourth quarter, doubling the US commercial installed base. Commercially contracted instruments in EMEA escalated by 16 during the same period.
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
Abbott announces quarterly common dividend
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli